NASDAQ:SOPH SOPHiA GENETICS (SOPH) Stock Price, News & Analysis → Could this Tiny Biotech End Disease Forever? (From Behind the Markets) (Ad) Free SOPH Stock Alerts $4.97 -0.08 (-1.58%) (As of 05/7/2024 ET) Add Compare Share Share Today's Range$4.75▼$5.2050-Day Range$4.21▼$5.6252-Week Range$2.13▼$7.37Volume263,135 shsAverage Volume60,029 shsMarket Capitalization$324.19 millionP/E RatioN/ADividend YieldN/APrice Target$8.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media Get SOPHiA GENETICS alerts: Email Address SOPHiA GENETICS MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside61.0% Upside$8.00 Price TargetShort InterestHealthy0.10% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.05Based on 7 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.02) to ($0.91) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.29 out of 5 starsMedical Sector555th out of 903 stocksBiological Products, Except Diagnostic Industry95th out of 153 stocks 3.5 Analyst's Opinion Consensus RatingSOPHiA GENETICS has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageSOPHiA GENETICS has only been the subject of 2 research reports in the past 90 days.Read more about SOPHiA GENETICS's stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.10% of the float of SOPHiA GENETICS has been sold short.Short Interest Ratio / Days to CoverSOPHiA GENETICS has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in SOPHiA GENETICS has recently decreased by 11.98%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldSOPHiA GENETICS does not currently pay a dividend.Dividend GrowthSOPHiA GENETICS does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for SOPH. Previous Next 1.7 News and Social Media Coverage News SentimentSOPHiA GENETICS has a news sentiment score of 0.05. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.38 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for SOPHiA GENETICS this week, compared to 2 articles on an average week. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, SOPHiA GENETICS insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.88% of the stock of SOPHiA GENETICS is held by insiders.Percentage Held by InstitutionsOnly 31.59% of the stock of SOPHiA GENETICS is held by institutions.Read more about SOPHiA GENETICS's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for SOPHiA GENETICS are expected to grow in the coming year, from ($1.02) to ($0.91) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of SOPHiA GENETICS is -4.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of SOPHiA GENETICS is -4.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSOPHiA GENETICS has a P/B Ratio of 1.57. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about SOPHiA GENETICS's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the MarketsFidelity, Bezos, Goldman Bet Big on Tiny BiotechAre you ready for a major shift in the investment world? There's a new drug The Wall Street Journal is calling the "King Kong" of drugs.Don't miss out on the "next Ozempic" >>> About SOPHiA GENETICS Stock (NASDAQ:SOPH)SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. The company offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific. SOPHiA GENETICS SA was incorporated in 2011 and is headquartered in Rolle, Switzerland.Read More SOPH Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SOPH Stock News HeadlinesMay 8, 2024 | msn.comSOPHiA Genetics GAAP EPS of -$0.21 beats by $0.06, revenue of $15.8M misses by $0.65MMay 7, 2024 | markets.businessinsider.comSOPHiA GENETICS SA is about to announce its earnings — here's what Wall Street expectsMay 8, 2024 | Behind the Markets (Ad)Could this Tiny Biotech End Disease Forever?Imagine a revolutionary treatment capable of editing out ANY disease. By literally "cutting" the genetic instructions that cause illness, and "pasting" in corrected DNA to restore perfect health.May 7, 2024 | msn.comSOPH Stock Earnings: Sophia Genetics Beats EPS, Beats Revenue for Q1 2024May 7, 2024 | globenewswire.comSOPHiA GENETICS Reports First Quarter 2024 ResultsMay 5, 2024 | americanbankingnews.comSOPHiA GENETICS (SOPH) to Release Quarterly Earnings on TuesdayApril 30, 2024 | uk.finance.yahoo.comSOPHiA GENETICS to Present at the 2024 RBC Capital Markets Global Healthcare ConferenceApril 30, 2024 | globenewswire.comSOPHiA GENETICS to Present at the 2024 RBC Capital Markets Global Healthcare ConferenceMay 8, 2024 | Behind the Markets (Ad)Could this Tiny Biotech End Disease Forever?Imagine a revolutionary treatment capable of editing out ANY disease. By literally "cutting" the genetic instructions that cause illness, and "pasting" in corrected DNA to restore perfect health.April 23, 2024 | msn.comShort on time? 10 books you can finish quickly.April 23, 2024 | finance.yahoo.comSOPHiA GENETICS to Announce Financial Results for First Quarter 2024 on May 7, 2024April 23, 2024 | prnewswire.comSOPHiA GENETICS Announces Syndicate Bio as First Liquid Biopsy Customer in AfricaApril 21, 2024 | finance.yahoo.comWe Think SOPHiA GENETICS (NASDAQ:SOPH) Can Afford To Drive Business GrowthApril 18, 2024 | investing.comUnilabs adopts SOPHiA GENETICS AI for cancer diagnosticsApril 17, 2024 | abcnews.go.com'Shopaholic' author Sophie Kinsella reveals brain cancer diagnosisApril 13, 2024 | msn.comRHOC’s Lauri Peterson Shares Glimpse Into ‘Saddest Day of My Life’ After Son Josh Waring’s DeathApril 13, 2024 | msn.comLeicester girl constantly on sedatives gets 'pacemaker for the brain'April 9, 2024 | markets.businessinsider.comRBC Capital Sticks to Its Buy Rating for SOPHiA GENETICS (SOPH)April 4, 2024 | prnewswire.comSOPHiA GENETICS and Strand Life Sciences Announce New Strategic PartnershipApril 2, 2024 | prnewswire.comLaboratorio Barnafi-Krause is Live on SOPHiA DDM™March 28, 2024 | msn.comAmericas dengue outbreak is the ‘worst to date’March 28, 2024 | msn.comA promising discovery in a rare neurodegenerative diseaseMarch 28, 2024 | msn.comDiscovering the Hidden Science of Everyday WondersMarch 21, 2024 | msn.comUSask and Sophia Genetics partner to improve ovarian cancer trialMarch 15, 2024 | finance.yahoo.comSOPHiA GENETICS and The French Kidney Cancer Research Network (UroCCR) Publish Results from Multiyear CollaborationMarch 14, 2024 | msn.comThe Worms of Chernobyl Have Apparently Conquered RadiationMarch 9, 2024 | finance.yahoo.comSOPHiA GENETICS SA (NASDAQ:SOPH) Just Released Its Yearly Results And Analysts Are Updating Their EstimatesSee More Headlines Receive SOPH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for SOPHiA GENETICS and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/05/2024Today5/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:SOPH CUSIPN/A CIK1840706 Webwww.sophiagenetics.com Phone41-21-694-1060FaxN/AEmployees430Year FoundedN/APrice Target and Rating Average Stock Price Target$8.00 High Stock Price Target$8.00 Low Stock Price Target$8.00 Potential Upside/Downside+61.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($1.22) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-78,980,000.00 Net Margins-126.63% Pretax Margin-125.85% Return on Equity-47.40% Return on Assets-36.43% Debt Debt-to-Equity RatioN/A Current Ratio4.16 Quick Ratio3.97 Sales & Book Value Annual Sales$62.37 million Price / Sales5.20 Cash FlowN/A Price / Cash FlowN/A Book Value$3.16 per share Price / Book1.57Miscellaneous Outstanding Shares65,230,000Free Float62,048,000Market Cap$324.19 million OptionableNot Optionable Beta1.12 (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report Key ExecutivesDr. Jurgi Camblong M.B.A. (Age 45)Ph.D., Co-Founder, CEO & Director Comp: $1.07MMr. Ross Jordan Muken B.Sc. (Age 43)Executive VP, CFO & COO Mr. Abhimanyu VermaSenior VP & CTODr. Zhenyu Xu Ph.D. (Age 41)Executive VP & Chief Scientific Officer Katherine BailonVice President of Investor RelationsMr. Daan van Well L.L.M. (Age 49)M.B.A., Executive VP, Chief Legal & Compliance Officer Ms. Manuela Da Silva Valente B.A. (Age 53)Senior VP & Chief People Officer Mr. Kevin PuylaertVP & MD of EMEADr. Philippe Menu M.B.A. (Age 42)M.D., Ph.D., Executive VP, Chief Medical Officer & Chief Product Officer Mr. Peter CasasantoSenior VP & Chief BioPharma OfficerMore ExecutivesKey CompetitorsVentyx BiosciencesNASDAQ:VTYXAnavex Life SciencesNASDAQ:AVXLCaribou BiosciencesNASDAQ:CRBUJasper TherapeuticsNASDAQ:JSPRMeiraGTxNASDAQ:MGTXView All CompetitorsInstitutional OwnershipEssex Investment Management Co. LLCBought 138,933 shares on 5/3/2024Ownership: 0.403%Moloney Securities Asset Management LLCBought 93,800 shares on 5/2/2024Ownership: 0.273%Principal Financial Group Inc.Bought 11,677 shares on 4/29/2024Ownership: 1.544%Essex Investment Management Co. LLCBought 123,901 shares on 2/8/2024Ownership: 0.000%View All Institutional Transactions SOPH Stock Analysis - Frequently Asked Questions Should I buy or sell SOPHiA GENETICS stock right now? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for SOPHiA GENETICS in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" SOPH shares. View SOPH analyst ratings or view top-rated stocks. What is SOPHiA GENETICS's stock price target for 2024? 2 equities research analysts have issued 1-year price objectives for SOPHiA GENETICS's shares. Their SOPH share price targets range from $8.00 to $8.00. On average, they expect the company's share price to reach $8.00 in the next twelve months. This suggests a possible upside of 61.0% from the stock's current price. View analysts price targets for SOPH or view top-rated stocks among Wall Street analysts. How have SOPH shares performed in 2024? SOPHiA GENETICS's stock was trading at $4.71 at the start of the year. Since then, SOPH stock has increased by 5.5% and is now trading at $4.97. View the best growth stocks for 2024 here. Are investors shorting SOPHiA GENETICS? SOPHiA GENETICS saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 52,600 shares, an increase of 22.3% from the March 15th total of 43,000 shares. Based on an average daily volume of 54,500 shares, the days-to-cover ratio is presently 1.0 days. Currently, 0.1% of the shares of the company are sold short. View SOPHiA GENETICS's Short Interest. When is SOPHiA GENETICS's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 13th 2024. View our SOPH earnings forecast. How were SOPHiA GENETICS's earnings last quarter? SOPHiA GENETICS SA (NASDAQ:SOPH) issued its earnings results on Tuesday, March, 5th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.25) by $0.12. The firm had revenue of $17.05 million for the quarter, compared to analysts' expectations of $16.78 million. SOPHiA GENETICS had a negative net margin of 126.63% and a negative trailing twelve-month return on equity of 47.40%. During the same period last year, the business earned ($0.22) earnings per share. What guidance has SOPHiA GENETICS issued on next quarter's earnings? SOPHiA GENETICS issued an update on its FY 2024 earnings guidance on Wednesday, May, 8th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $78.0 million-$81.0 million, compared to the consensus revenue estimate of $79.2 million. When did SOPHiA GENETICS IPO? SOPHiA GENETICS (SOPH) raised $234 million in an initial public offering on Friday, July 23rd 2021. The company issued 13,000,000 shares at $17.00-$19.00 per share. Who are SOPHiA GENETICS's major shareholders? SOPHiA GENETICS's stock is owned by many different institutional and retail investors. Top institutional investors include Principal Financial Group Inc. (1.54%), Essex Investment Management Co. LLC (0.40%) and Moloney Securities Asset Management LLC (0.27%). How do I buy shares of SOPHiA GENETICS? Shares of SOPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:SOPH) was last updated on 5/8/2024 by MarketBeat.com Staff From Our PartnersThe Department of Defense Has a New Drone ContractorThe Tomorrow InvestorTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaShocking: One AI startup's revenue could surge 4,735%Manward PressAI “wealth window” is closing June 25thParadigm PressClaim Your Complimentary Bitcoin RewardCrypto Swap ProfitsGold Set to EXPLODE!Gold Safe ExchangeThe #1 lithium battery stock to have on your radar in 2024!Smallcaps DailyForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill Publishing Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding SOPHiA GENETICS SA Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
